Aggrastat®

Ingredient

Each mL contains Tirofiban Hydrochloride Monohydrate-0.281mg (as Tirofiban
0.25mg)

Content

0.25mg/mL

Indication

AGGRASTAT, in combination with heparin,
is indicated for the treatment of acute coronary syndrome, including patients
who are to be managed medically and those undergoing percutaneous transluminal
coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been
shown to decrease the rate of a combined endpoint of death, new myocardial
infarction or refractory ischemia/repeat cardiac procedure.

Allegra tablet 30mg

Ingredient

fexofenadine hydrochloride

Content

30mg

Indication

Relief of symptoms associated with seasonal allergic rhinitis and  allergic dermatitis (chronic idiopathic urticaria) in children 6-11 years of age.

Allegra tablet 120mg

Ingredient

120mg

Content

120mg

Indication

Relief of symptoms associated with allergic rhinitis in adults and children 12 years of age and older.

Allegra® tablet 180mg

Ingredient

fexofenadine hydrochloride

Content

180mg

Indication

Relief of symptoms associated with allergic skin disease(chronic idiopathic urticarcia) in adults and children 12 years of age and older

Amaryl M tablet

Ingredient

1/250mg : glimepiride 1mg, metformin hydrochloride 250mg
2/500mg : glimepiride 2mg, metformin hydrochloride 500mg
1/500mg : glimepiride 1mg, metformin hydrochloride 500mg

Content

1/250mg, 2/500mg, 1/500mg

Indication

As an adjunct to diet and exercise in NIDDM (type 2) patients

– In case that the monotherapy with sulfonylurea or metformin does not result in adequate glycemic control

– Replacement of combination therapy of sulfonylurea and metformin

Amaryl Mex tablet

Ingredient

glimepiride/metformin hydrochloride

Content

2mg/500mg

Indication

As an adjunct to diet and exercise in NIDDM (type 2) patients

– In case that the monotherapy with sulfonylurea or metformin does not result in adequate glycemic control

– Replacement of combination therapy of sulfonylurea and metformin

Amaryl tablet

Ingredient

glimepiride

Content

1mg/2mg/4mg

Indication

Treatment of type II diabetics

Arixtra® Injection (Pre-filled)

Ingredient

Each pre-filled syringe (0.5 ml) contains 2.5 mg of fondaparinux sodium

Content

2.5mg/pre-filled syringe(0.5mL)

Indication

1. Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
2. Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery
3. Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
4. Treatment in patients with UA/NSTEMI (Unstable Angina/Non-ST-segment Elevation Myocardial Infarction) not undergoing PCI

5. Treatment in patients with STEMI (ST-segment Elevation Myocardial Infarction) either treated with thrombolytic drugs or not undergoing reperfusion therapy